Patients’ individual genomes may affect efficacy, safety of gene editing
Gene editing has begun to be tested in clinical trials, using CRISPR-Cas9 and other technologies to directly edit DNA inside people’s cells, and multiple trials are recruiting or in the planning stages. A new study led by Boston Children’s Hospital and the University of Montreal raises a note of caution, finding that person-to-person genetic differences may undercut the efficacy of the gene editing process or, in more rare cases, cause a potentially dangerous “off target” effect.
The study adds to evidence that gene editing may need to be adapted to each patient’s genome, to ensure there aren’t variants in DNA sequence in or near the gene being targeted that would throw off the technology. Findings appear this week in the Proceedings of the National Academy of Sciences Early Edition (December 11-15).
“Humans vary in their DNA sequences, and what is taken as the ‘normal’ DNA sequence for reference cannot account for all these differences,” says Stuart Orkin, MD, of Dana-Farber Boston Children’s Cancer and Blood Disorders Center and co-corresponding author on the study with Matthew Canver, an MD-PhD student at Harvard Medical School. “We recommend that common variation be taken into account in designing targeting systems for therapeutic editing, to maximize efficacy and minimize potential safety concerns.”
The study analyzed 7,444 previously published whole-genome sequences. Based on a list of about 30 disease-related DNA targets that researchers are interested in altering through gene editing, the researchers made a second list of nearly 3,000 guide RNAs (gRNAs). These are bits of genetic code that have been developed to direct CRISPR-Cas9 enzymes to the right editing location on or adjacent to the target, like the address on an envelope.
The team, led by Orkin, Canver and Samuel Lessard of the University of Montreal, then looked to see whether any of the 7,444 individuals carried DNA sequence variants (“letter changes” or insertions/deletions) in the areas the gRNAs are looking for.
“If there are genetic differences at the site that CRISPR reagents are targeting for therapy, you are at risk for decreased efficacy or treatment failure,” explains Canver, who conceived and led the study in Orkin’s Boston Children’s Hospital lab. “A difference in just a single base pair can cause a decrease in binding efficiency due to a mismatch with the guide RNA. Overall, this can cause a reduction in treatment efficacy.”
The team found that such occurrences in the genome are not uncommon; about 50 percent of the analyzed gRNAs had the potential to be affected by variants at their target sites. In a few cases, the team found genetic variants that cause DNA sequences in the genome to more closely match a gRNA that could potentially draw it to the wrong place — resulting in an edit of a gene or other DNA region that’s not meant to be targeted.
“In rare cases, there was the potential to create very potent ‘off-target’ sites – where CRISPR reagents could bind and cut where they’re not intended to,” says Canver. “If an off-target effect happens to be in, say, a tumor suppressor gene, that would be a big concern.”
Although the study looked at CRISPR-Cas9 gene editing, the researchers believe their findings extend to other gene-editing tools such as zinc-finger nucleases (ZFN) and TAL effector nucleases.
“The unifying theme is that all these technologies rely on identifying stretches of DNA bases very specifically,” says Canver. “So, a variant that affects the target sequence could reduce guide RNA binding. Variants can also lead to binding at new sites that could potentially cause harm. As these gene-editing therapies continue to develop and start to approach the clinic, it’s important to make sure each therapy is going to be tailored to the patient that’s going to be treated.”
The Latest on: Gene editing
- Students Practice Gene Editing With CRISPRon January 21, 2022 at 3:24 pm
Above: Isabelle Cambio handles the DNA while Lillian Zarrella observes. By Alana Modi and Ariana Davoudi In Mr. Nicholas Rath’s biotechnology class at East Greenwich High School, students recently got ...
- BioTechniques' Top Five CRISPR Gene Editing Startup Companieson January 21, 2022 at 1:27 pm
Five of the companies that are driving change in biotechnology and biomedicine with CRISPR gene editing. Since Crick and Watson discovered DNA''s structure in the 1950s, scientists have developed a ...
- New study highlights gulf between gene editing and conventional breedingon January 20, 2022 at 3:39 am
In nature, certain areas of the genome are protected from mutations – findings have huge implications for our understanding of gene editing as well as evolutionary theory. Report: Claire Robinson ...
- UK moves closer to allowing gene editing of crops by allowing more researchon January 19, 2022 at 9:00 pm
Government says gene editing can develop climate crisis resistant crops while critics fear it is another step towards GM ...
- Targeting Proteins Linked to Huntington's & ALS With a New Gene Editing Toolon January 19, 2022 at 7:27 pm
The CRISPR gene editing tool is often used with an enzyme called Cas9, which targets and cuts genomic DNA. While this technology has led to many breakthroughs | Genetics And Genomics ...
- Discovery of a 'hidden gem' enables gene editing with a small but mighty CRISPR-Cas3 systemon January 19, 2022 at 10:10 am
Nearly a decade ago, scientists discovered the power of CRISPR, a tool employed by bacteria to protect themselves against viral invaders. This system is now a fundamental research tool used for ...
- Editas (EDIT) Focuses on Developing Gene-Editing Eye Drugon January 19, 2022 at 9:01 am
Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.
- New Gene Editing ETF, XDNA, Offers Investors Exposure to the Next Great Biotech Innovationon January 14, 2022 at 8:22 am
The home for biotech innovators, @Nasdaq has a consistent eye toward the next revolutionary biotechnology. Today, Kelly ETF’s is launching a new exchange-traded fund (ETF), The Kelly CRISPR & Gene ...
- Virus-like particles as delivery vehicles for gene-editingon January 13, 2022 at 5:00 pm
Scientists deliver gene-editing proteins through the use of engineered virus-like particles, which mediated efficient base editing both in vitro and in vivo.
- Engineered particles efficiently deliver gene editing proteins to cells in miceon January 12, 2022 at 5:19 am
Gene editing approaches promise to treat a range of diseases, but delivering editing agents to cells in animal models and humans safely and efficiently has proven challenging. Now, researchers led by ...
via Google News and Bing News